• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

HES6 通过调节氧化磷酸化通路促进肺腺癌中 CD8+T 细胞浸润。

HES6 Mediates Oxidative Phosphorylation Pathway to Promote Immune Infiltration of CD8 + T Cells in Lung Adenocarcinoma.

机构信息

Department of Thoracic Surgery, Sir Run Run Shaw Hospital, School of Medicine, Zhejiang University, Hangzhou, China.

Department of Thoracic Surgery, Xinchang County People's Hospital, Xinchang, China.

出版信息

J Immunother. 2024 Oct 1;47(8):313-322. doi: 10.1097/CJI.0000000000000535. Epub 2024 Jul 15.

DOI:10.1097/CJI.0000000000000535
PMID:39005046
Abstract

Tumor immunotherapy has recently gained popularity as a cancer treatment strategy. The molecular mechanism controlling immune infiltration in lung adenocarcinoma (LUAD) cells, however, is not well characterized. Investigating the immune infiltration modulation mechanism in LUAD is crucial. LUAD patient samples were collected, and HES6 expression and immune infiltration level of CD8 + T cells in patient tissues were analyzed. Bioinformatics was utilized to identify binding relationship between E2F1 and HES6, and enrichment pathway of HES6. The binding of E2F1 to HES6 was verified using dual-luciferase and ChIP experiments. HES6 and E2F1 expression in LUAD cells was detected. LUAD cells were co-cultured with CD8 + T cells, and the CD8 + T cell killing level, IFN-γ secretion, and CD8 + T-cell chemotaxis level were measured. Expression of key genes involved in oxidative phosphorylation was detected, and the oxygen consumption rate of LUAD cells was assessed. A mouse model was constructed to assay Ki67 expression and apoptosis in tumor tissue. High expression of HES6 promoted CD8 + T-cell infiltration and enhanced T-cell killing ability through oxidative phosphorylation. Further bioinformatics analysis, molecular experiments, and cell experiments verified that E2F1 negatively regulated HES6 by oxidative phosphorylation, which suppressed CD8 + T-cell immune infiltration. In addition, in vivo assays illustrated that silencing HES6 repressed tumor cell immune evasion. E2F1 inhibited HES6 transcription, thereby mediating oxidative phosphorylation to suppress immune infiltration of CD8 + T cells in LUAD. The biological functions and signaling pathways of these genes were analyzed, which may help to understand the possible mechanisms regulating immune infiltration in LUAD.

摘要

肿瘤免疫疗法最近作为癌症治疗策略受到关注。然而,控制肺腺癌(LUAD)细胞免疫浸润的分子机制尚未得到很好的描述。研究 LUAD 中免疫浸润的调节机制至关重要。收集 LUAD 患者样本,分析患者组织中 CD8+T 细胞的 HES6 表达和免疫浸润水平。利用生物信息学方法鉴定 E2F1 与 HES6 的结合关系及 HES6 的富集通路。通过双荧光素酶和 ChIP 实验验证 E2F1 与 HES6 的结合。检测 LUAD 细胞中 HES6 和 E2F1 的表达。将 LUAD 细胞与 CD8+T 细胞共培养,检测 CD8+T 细胞的杀伤水平、IFN-γ 分泌水平和 CD8+T 细胞趋化水平。检测参与氧化磷酸化的关键基因的表达,并评估 LUAD 细胞的耗氧率。构建小鼠模型,检测肿瘤组织中 Ki67 的表达和细胞凋亡。高表达 HES6 通过氧化磷酸化促进 CD8+T 细胞浸润,增强 T 细胞杀伤能力。进一步的生物信息学分析、分子实验和细胞实验验证了 E2F1 通过氧化磷酸化负调控 HES6,抑制 CD8+T 细胞免疫浸润。此外,体内实验表明,沉默 HES6 抑制肿瘤细胞的免疫逃避。E2F1 抑制 HES6 转录,从而介导氧化磷酸化抑制 LUAD 中 CD8+T 细胞的免疫浸润。分析这些基因的生物学功能和信号通路,可能有助于理解调节 LUAD 中免疫浸润的可能机制。

相似文献

1
HES6 Mediates Oxidative Phosphorylation Pathway to Promote Immune Infiltration of CD8 + T Cells in Lung Adenocarcinoma.HES6 通过调节氧化磷酸化通路促进肺腺癌中 CD8+T 细胞浸润。
J Immunother. 2024 Oct 1;47(8):313-322. doi: 10.1097/CJI.0000000000000535. Epub 2024 Jul 15.
2
FOXA1/UBE2T Inhibits CD8T Cell Activity by Inducing Mediates Glycolysis in Lung Adenocarcinoma.FOXA1/UBE2T 通过诱导肺腺癌中的糖酵解来抑制 CD8T 细胞的活性。
Front Biosci (Landmark Ed). 2024 Apr 1;29(4):134. doi: 10.31083/j.fbl2904134.
3
TOX correlates with prognosis, immune infiltration, and T cells exhaustion in lung adenocarcinoma.TOX 与肺腺癌的预后、免疫浸润和 T 细胞耗竭相关。
Cancer Med. 2020 Sep;9(18):6694-6709. doi: 10.1002/cam4.3324. Epub 2020 Jul 23.
4
SFTPA1 is a potential prognostic biomarker correlated with immune cell infiltration and response to immunotherapy in lung adenocarcinoma.SFTPA1 是肺腺癌中与免疫细胞浸润和免疫治疗反应相关的潜在预后生物标志物。
Cancer Immunol Immunother. 2022 Feb;71(2):399-415. doi: 10.1007/s00262-021-02995-4. Epub 2021 Jun 28.
5
Transcription Factor ETV4 Activates AURKA to Promote PD-L1 Expression and Mediate Immune Escape in Lung Adenocarcinoma.转录因子 ETV4 通过激活 AURKA 促进肺腺癌中 PD-L1 的表达并介导免疫逃逸。
Int Arch Allergy Immunol. 2024;185(9):910-920. doi: 10.1159/000537754. Epub 2024 May 23.
6
New link between RNH1 and E2F1: regulates the development of lung adenocarcinoma.RNH1 与 E2F1 之间的新联系:调节肺腺癌的发展。
BMC Cancer. 2024 May 24;24(1):635. doi: 10.1186/s12885-024-12392-6.
7
Correlation between prognostic indicator AHNAK2 and immune infiltrates in lung adenocarcinoma.肺腺癌中预后标志物 AHNAK2 与免疫浸润的相关性。
Int Immunopharmacol. 2021 Jan;90:107134. doi: 10.1016/j.intimp.2020.107134. Epub 2020 Nov 7.
8
Comprehensive Analysis of YTH Domain Family in Lung Adenocarcinoma: Expression Profile, Association with Prognostic Value, and Immune Infiltration.肺腺癌中 YTH 结构域家族的综合分析:表达谱、与预后价值的关联和免疫浸润。
Dis Markers. 2021 Aug 26;2021:2789481. doi: 10.1155/2021/2789481. eCollection 2021.
9
Increased expression of TTC21A in lung adenocarcinoma infers favorable prognosis and high immune infiltrating level.TTC21A 在肺腺癌中的高表达预示着良好的预后和高水平的免疫浸润。
Int Immunopharmacol. 2020 Jan;78:106077. doi: 10.1016/j.intimp.2019.106077. Epub 2019 Dec 5.
10
The role of EMG1 in lung adenocarcinoma progression: Implications for prognosis and immune cell infiltration.EMG1 在肺腺癌进展中的作用:对预后和免疫细胞浸润的影响。
Int Immunopharmacol. 2024 Sep 10;138:112553. doi: 10.1016/j.intimp.2024.112553. Epub 2024 Jun 28.

引用本文的文献

1
Pan-cancer analysis reveals dual roles of HES6 in cancer immunity and prognosis.泛癌分析揭示了HES6在癌症免疫和预后中的双重作用。
Discov Oncol. 2025 Jun 15;16(1):1110. doi: 10.1007/s12672-025-02852-1.
2
SCGB3A1-Epi and KLK10-Epi Crosstalk With Fibroblasts Promotes Liver Metastasis of Breast Cancer and Pancreatic Ductal Adenocarcinoma.SCGB3A1-Epi和KLK10-Epi与成纤维细胞的相互作用促进乳腺癌和胰腺导管腺癌的肝转移。
Cancer Med. 2025 May;14(9):e70904. doi: 10.1002/cam4.70904.